Clinical trials recruiting in Madrid, Spain

Phase breakdown

Conditions recruiting in Madrid, Spain

Recruiting trials in Madrid, Spain

• "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition"
  NCT06857929 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years to 50 Years · Sex: All (male and female)
• #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.
  NCT06900829 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
  NCT07190248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  NCT07227597 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  NCT06863272 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
  NCT06961006 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
  NCT07266831 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
  NCT06428409 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  NCT07060807 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
  NCT07218029 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
  NCT06931717 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
  NCT07079631 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
  NCT07070232 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
  NCT07554339 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
  NCT07018713 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
  NCT07018700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
  NCT07111520 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
  NCT07186842 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
  NCT06872125 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
  NCT07227857 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 12 Years · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
  NCT06868277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT06405087 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
  NCT07250802 · Phase: Phase 3 · Ages: 4 Years to 17 Years · Sex: All (male and female)
• A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
  NCT06747949 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-term Extension Study of PCI-32765 (Ibrutinib)
  NCT01804686 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
  NCT07003425 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
  NCT04641247 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
  NCT07260877 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
  NCT07161258 · Phase: Phase 2 · Ages: 10 Years to 17 Years · Sex: All (male and female)
• A Phase 1/1b Study of IAM1363 in HER2 Cancers
  NCT06253871 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
  NCT06570798 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
  NCT07102381 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
  NCT06680830 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
  NCT06226883 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
  NCT07005154 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
  NCT07202546 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
  NCT03394365 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
  NCT06660394 · Phase: Phase 3 · Ages: 2 Years to 65 Years · Sex: All (male and female)
• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
  NCT07405801 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
  NCT06103864 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
  NCT07662135 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
  NCT07226986 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
  NCT06996782 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
  NCT05708235 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
  NCT02819882 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
  NCT05489705 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07196748 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
  NCT07172516 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
  NCT05716100 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
  NCT06979375 · Phase: Phase 2 · Ages: 40 Years to 84 Years · Sex: All (male and female)
• A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
  NCT06979362 · Phase: Phase 2 · Ages: 40 Years to 84 Years · Sex: All (male and female)
• A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
  NCT06717698 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
  NCT07668388 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07481630 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
  NCT06609226 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female)
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
  NCT06528314 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
  NCT06215716 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
  NCT05920356 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
  NCT06790693 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
  NCT05646862 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
  NCT04802759 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
  NCT04929223 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
  NCT05789082 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
  NCT05800665 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male
• A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
  NCT05076175 · Phase: Phase 2, Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT07680764 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study With CIT-013 in RA Patients
  NCT06567470 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
  NCT04965675 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female)
• A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
  NCT05164172 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of AZD0120 in Autoimmune Diseases
  NCT07295847 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
  NCT06875310 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  NCT06369285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
  NCT05379595 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
  NCT06750094 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  NCT06662786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT06667076 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  NCT05498428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
  NCT07492680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
  NCT03526835 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)

Showing 100 of 682 recruiting trials.

Common questions

How many clinical trials are recruiting in Madrid, Spain?

682 recruiting trials have at least one study site in Madrid, Spain.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.